for people ages 18 years and up (full criteria)
at San Francisco, California and other locations
study started
estimated completion



This is a phase IV, multi-center, double-blind, randomized, placebo- controlled study evaluating the effect of alirocumab on SVG atherosclerotic disease burden, as assessed by IVUS at baseline and following 78 weeks of treatment in subjects with at least one intermediate SVG lesion receiving optimal statin therapy. Subjects will be randomized 1:1 into 2 treatment groups: alirocumab 150 mg subcutaneously every 2 weeks or placebo subcutaneously every 2 weeks.

Official Title

Effect of Alirocumab on Saphenous Vein Graft Atherosclerosis: The Alirocumab for Stopping Atherosclerosis Progression in Saphenous Vein Grafts (ASAP-SVG) Pilot Trial


Saphenous Vein Graft Atherosclerosis Atherosclerosis Alirocumab 150 MG/ML subcutaneous injection


You can join if…

Open to people ages 18 years and up

  1. Age 18 years or greater.
  2. Willing and able to give informed consent. The patients must be able to comply with study procedures and follow-up.
  3. Undergoing clinically-indicated coronary and SVG angiography.
  4. Have at least one target saphenous vein graft with an intermediate SVG lesion (defined as a lesion with 30-60% angiographic diameter stenosis) amenable to examination with IVUS. The SVG should have no thrombus or ulceration and should not be considered responsible for the patient's clinical presentation and referral for angiography.
  5. Receiving optimal statin therapy defined as use of a high intensity statin (atorvastatin 40-80 mg daily or rosuvastatin 20-40 mg daily), any statin therapy with achieved LDL-C level <70mg/dL, or maximally-tolerated statin dose for patients who are statin intolerant statin.

You CAN'T join if...

  1. Positive pregnancy test or breast-feeding.
  2. Coexisting conditions that limit life expectancy to less than 18 months or that could affect a patient's compliance with the protocol.
  3. Estimated glomerular filtration rate (eGFR) <30 ml/min/1.73m2.
  4. Severe peripheral arterial disease limiting vascular access.
  5. History of allergic reaction to iodine-based contrast agents that cannot be premedicated.
  6. Known hypersensitivity to alirocumab.
  7. Any prior use of proprotein convertase subtilisin/kexin type 9 (PCSK9) inhibitor therapy.


  • San Francisco VA Medical Center
    San Francisco California 94121 United States
  • Dallas VA Medical Center
    Dallas Texas 75216 United States


accepting new patients by invitation only
Start Date
Completion Date
Minneapolis Heart Institute Foundation
Phase 4
Study Type
Last Updated